Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
Ravikirti, Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Majhi, Deependra Kumar Rai, Shyama, Anjani Kumar, Asim Sarfaraz
doi: https://doi.org/10.1101/2021.01.05.21249310
Ravikirti
1Department of General Medicine, All India Institute of Medical Sciences (AIIMS), Patna, India
Roles: Additional Professor and Head
Ranjini Roy
2Department of General Medicine, AIIMS, Patna, India
Roles: Postgraduate Trainee
Chandrima Pattadar
2Department of General Medicine, AIIMS, Patna, India
Roles: Postgraduate Trainee
Rishav Raj
3Department of General Medicine, AIIMS, Patna
Roles: Postgraduate Trainee
Neeraj Agarwal
4Department of Community and Family Medicine, AIIMS, Bibi Nagar, India
Roles: Professor and Head
Bijit Biswas
5Department of Community and Family Medicine, AIIMS, Patna, India
Roles: Senior Resident
Pramod Kumar Majhi
6Department of Pharmacology, AIIMS, Patna, India
Roles: Assistant Professor and Head
Deependra Kumar Rai
7Department of Pulmonary Medicine, AIIMS, Patna, India
Roles: Additional Professor and Head
Shyama
3Department of General Medicine, AIIMS, Patna
Roles: Assistant Professor
Anjani Kumar
3Department of General Medicine, AIIMS, Patna
Roles: Assistant Professor
Asim Sarfaraz
9Department of Microbiology, AIIMS, Patna
Roles: Assistant Professor
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article usage
Posted January 09, 2021.
Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
Ravikirti, Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Majhi, Deependra Kumar Rai, Shyama, Anjani Kumar, Asim Sarfaraz
medRxiv 2021.01.05.21249310; doi: https://doi.org/10.1101/2021.01.05.21249310
Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
Ravikirti, Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Majhi, Deependra Kumar Rai, Shyama, Anjani Kumar, Asim Sarfaraz
medRxiv 2021.01.05.21249310; doi: https://doi.org/10.1101/2021.01.05.21249310
Subject Area
Subject Areas
- Addiction Medicine (329)
- Allergy and Immunology (648)
- Anesthesia (173)
- Cardiovascular Medicine (2484)
- Dermatology (209)
- Emergency Medicine (384)
- Epidemiology (11947)
- Forensic Medicine (10)
- Gastroenterology (714)
- Genetic and Genomic Medicine (3874)
- Geriatric Medicine (358)
- Health Economics (648)
- Health Informatics (2503)
- Health Policy (963)
- Hematology (350)
- HIV/AIDS (812)
- Medical Education (384)
- Medical Ethics (106)
- Nephrology (411)
- Neurology (3638)
- Nursing (204)
- Nutrition (542)
- Oncology (1887)
- Ophthalmology (549)
- Orthopedics (229)
- Otolaryngology (298)
- Pain Medicine (240)
- Palliative Medicine (71)
- Pathology (459)
- Pediatrics (1066)
- Primary Care Research (434)
- Public and Global Health (6305)
- Radiology and Imaging (1335)
- Respiratory Medicine (845)
- Rheumatology (388)
- Sports Medicine (333)
- Surgery (424)
- Toxicology (51)
- Transplantation (179)
- Urology (152)